Phone: +61 (0)400 797 309 Citation: Yeap I, Ahn C, Hoffman S, Gillies R, Vandervord J. Current evidence for outcomes of free-flap reconstruction in factor V Leiden. Aust J Plast Surg. 2019;2(2):58-66. https:// Abstract Background: Factor V Leiden is the most common form of inherited thrombophilic syndrome, affecting 5 per cent of caucasians. While increased rates of venous thromboembolic complications have been regularly reported in factor V Leiden patients, little is known about their risk of microvascular complications or flap failure rates in free-flap surgery. The aim of this review is to qualitatively review the published literature on outcomes of free-flap surgery in patients with factor V Leiden.
Introduction
Factor V Leiden is a hereditary condition resulting in a mutation of the genetic composition of factor V, a clotting factor that forms part of the intrinsic clotting cascade. The mutation results in resistance against the normal degradation of factor V by activated protein C, leading to abnormally increased clotting. The risk of developing abnormal blood clots in heterozygous factor V Leiden patients is three to eight times the risk in the general population, while the risk for homogeneous patients can be as high as one in 12, or an 80-fold relative risk. 1, 2 Of the inherited thrombophilias, factor V Leiden is the most common: 5 per cent of Caucasians are affected, although incidence rates in other races are much lower than this. 1 Inherited in an autosomal dominant manner, the incidence of those homozygous for the condition is estimated at less than 0.25 per cent, while the incidence of those heterozygous for the condition is 3-7 per cent. 3 The prevalence in Caucasian Australians is even higher, with a newborn screening study finding 9.5 per cent of the population to be heterozygous. 4 Microvascular free-flap reconstruction allows for the reconstruction of complex defects not amenable to repair by other reconstructive options. 5, 6 Free-tissue transfer involves the reconstitution of blood supply to the transferred tissue via microanastomosis of the artery and/ or vein. The most significant morbidity in this process is flap failure due to thrombosis at the anastomotic site, both venous and arterial.
Prevention of thrombotic complications typically involves careful vessel dissection and handling, meticulous surgical technique and well-described adjuncts such as heparin, aspirin and dextran. 7, 8 However, the literature supporting the use of these agents is varied and inconclusive. 7 Perhaps more important is the preoperative planning duplicates. The two lead authors screened the titles and abstracts of these 217 articles and excluded studies that did not focus on free-flap surgery, did not differentiate between different types of hereditary thrombophilia, such that patients with factor V Leiden could be isolated out, or were not in English. Studies related to digit transplantation were excluded. Thirty-nine full-text studies were then assessed for eligibility, resulting in seven studies that met the inclusion criteria. Through examining the reference lists of these seven studies, three additional studies that met the inclusion criteria were identified. It was noted that Wang and colleagues wrote two case series in 2012 and both included a patient with factor V Leiden. 12, 13 Only the case series with the greater number of patients with factor V Leiden was included in this review, since we did not want to count the same patient twice. Nine case studies or series (level IV evidence) were included in this review.
Results
Despite factor V Leiden being a relatively common and well-studied condition, literature on whether or not it affects outcomes in free-flap surgery is scant and limited to level IV evidence (case studies and reviews). Only nine studies, involving 22 patients in total, were found. These studies are outlined in Table 1 . For many of the included cases, data on patients with factor V Leiden were extrapolated from studies on patients with thrombophilias in general. 12, 14, 15 Of the 22 patients, three had factor V Leiden where it was not specified whether or not they were homozygous or heterozygous, 12,17 12 were heterozygous with unspecified mutations, 16,18 two were heterozygous with the G1691A mutation, 15, 19 one was heterozygous with the R506Q mutation, 17 one was a compound heterozygote (G169A and A4070G) with other thrombophilic mutations, 20 two were heterozygotes (R506Q) with other thrombophilic mutations 14 and one was a heterozygote (mutation not specified) with other thrombophilic mutations. 21 Table 2 stratifies the patients and cases by their mutation type and compares mutation type with whether or not the free-flap survived.
Results from the current literature suggest that even heterozygous factor V Leiden patients have a relatively high risk of free-flap failure of 3/15 free flaps (20%). Patients who were heterozygous for factor V Leiden and had other coexistent thrombophilias had an even higher failure rate of 5/6 free flaps (83.3%). Importantly, these values do not control for the different types of antithrombotic treatments used across the various studies. A deliberate decision was made not to generate summary statistics such as odds ratios and relative risks because the sample size was too small and the quality of evidence too low. including thrombophilias, has become more significant than the relative influence of surgical factors on free-flap outcomes.
Discussion

Limitations of the literature
Clinical implications: a role for preoperative screening strategies
Free-tissue transfer is the most complex technique in the reconstructive surgeon's armamentarium.
As such, failure may result in a patient being left with no reconstructive options other than another free flap. 5, 6 Flap loss results in stress for both the patient and the surgeon, with a long list of subsequent complications including exposure of essential structures and hardware, leaks or fistulas and the need for multiple repeat operations. Thus, failed free flaps represent a significant cost not just for the patient, but also for the healthcare system. 5, 41, 42 In Australia, the cost of flap salvage has been estimated at $3045 and the cost of replacing a flap with a new free flap has been estimated at $5075.21. Nevertheless, given the significant economic and psychological costs associated with failed free-flap reconstructions, the use of a simple, non-invasive screening protocol has significant potential. We agree with the recommendation of Pannucci,
Kovach and Cuker 38 that institutions would benefit from having a preoperative screening protocol that involves taking a thorough history and then referring high-risk patients for haematology review. Beyond this, it is up to the discretion of the surgical department whether they adopt a radical approach of not offering free flaps to any patients with factor V Leiden (including heterozygotes), or whether they simply work with the haematologist to minimise the patient's risk through a combination of more aggressive chemoprophylaxis, meticulous surgical technique, more frequent postoperative flap monitoring and educating the patient on his/ her increased risk profile.
Such an approach has many merits: it is cost-saving, easy to implement and could foster stronger crossdiscipline collaboration between plastic surgeons and haematologists. Scope for further research includes whether or not adopting such a protocol would be cost-saving for an institution or lead to fewer free-flap complications. Further study should also be undertaken into the molecular pathways involved in microvascular thrombotic events and whether or not such pathways are altered in patients with factor V Leiden.
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